tbuckley/cabot-search huggingface dataset:
Most fatal opioid overdoses are not caused by prescription drugs, US study finds
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Most fatal opioid overdoses are caused by illicitly made fentanyl and heroin, rather than prescription opioids, according to a study looking at deaths in the US state of Massachusetts.1

The study, which analysed opioid toxicology reports between 2013 and 2015, said prescribed opioid exposure appeared to have a “more distal” effect on overdose risk, by acting as a gateway drug.

The researchers have now called on policymakers to focus on “educating, engaging, and treating people who use illicitly made fentanyl and heroin” alongside work to prevent the misuse of prescription opioids.

In the US in the 1990s and early 2000s, annual increases in opioid related overdose deaths paralleled increases in opioid prescriptions for pain. But since 2010, opioid prescribing has levelled and declined while opioid related overdose deaths have …
The Selective Bcl-2 Inhibitor ABT-199 Synergizes with BTK or Proteasome Inhibitors to Induce Potent Cell Death in Preclinical Models of Bortezomib or Ibrutinib-Resistant Waldenströms Macroglobulinemia
Authors: Kasyapa S. Chitta, Aneel Paulus, Maja Blake-Kuranz, Sharoon Akhtar, Anne J. Novak, Stephen M. Ansell, Robert Kyle, Morie A Gertz, Peter Martin, Morton Coleman, Sikander Ailawadhi, Asher Chanan-Khan
Journal: Blood (2014)
Correlation of Telomere Length in Blood, Buccal Cells, and Fibroblasts From Patients with Inherited Bone Marrow Failure Syndromes.
Authors: Shahinaz M Gadalla, Richard Cawthon, Neelam Giri, Gabriela Baerlocher, Peter M. Lansdorp, Blanche P. Alter, Sharon A Savage
Journal: Blood (2009)
NOTCH1 Mutations Are Associated with Low CD20 Expression in Chronic Lymphocytic Leukemia: Evidences for a NOTCH1-Mediated Epigenetic Regulatory Mechanism
Authors: Federico Pozzo, Tamara Bittolo, Pietro Bulian, Erika Tissino, Francesca Maria Rossi, Paolo Macor, Riccardo Bomben, Antonella Zucchetto, Dania Benedetti, Francesca Arruga, Branimir Gizdic, Massimo Degan, Giovanni D'Arena, Francesco Di Raimondo, Francesco Zaja, Gabriele Pozzato, Silvia Deaglio, Davide Rossi, Gianluca Gaidano, Giovanni Del Poeta, Valter Gattei, Michele Dal Bo
Journal: Blood (2014)
Bone‐Fibrocartilage‐Tendon Composites: Preparation of Decellularized Triphasic Hierarchical Bone‐Fibrocartilage‐Tendon Composite Extracellular Matrix for Enthesis Regeneration (Adv. Healthcare Mater. 19/2019)
Authors: Mingzhen Su, Qi Zhang, Yiwei Zhu, Shengyu Wang, Jiawen Lv, Jiaan Sun, Pengchen Qiu, Shunwu Fan, Keke Jin, Lei Chen, Xianfeng Lin
Journal: Advanced Healthcare Materials (2019)

In article number 1900831, Keke Jin, Lei Chen, Xianfeng Lin, and co-workers, apply specific decellularization schemes for bone-fibrocartilagetendon (BFT) triphasic composites based on corresponding tissue specificity, and the integrated structures and biocomponents of the BFT scaffold after decellularization process with good biocompatibility and the ability to induce MSCs specific differentiations (osteogenic and myotendinous) in vitro, as well as superior ability to promote enthesis regeneration in vivo that are well preserved.
The Effect of Bortezomib Containing Induction On the Long Term Outcome of autologous Haemopoietic Stem Cell Transplantation in Multiple Myeloma Patients Outside Clinical Trials - a Single Center Experience
Authors: Miklos Udvardy, Remenyi Gyula, Attila Kiss, Peter Batar, Arpad Illes, Laszló Varoczy, Gaspar Radvanyi, Robert Szasz, Laszlo Rejto
Journal: Blood (2012)
ARID5B Regulates Leukemia Sensitivity to Antimetabolites in Children with Acute Lymphoblastic Leukemia Via Effects on Cell Cycle Progression
Authors: Jun J. Yang, Heng Xu, Deepa Bhojwani, Takaya Moriyama, Maoxiang Qian, Xue Yang, Nita L. Seibel, Mary V. Relling, William L. Carroll, Ching-Hon Pui, William E. Evans
Journal: Blood (2014)
Mutational Spectrum of Stromal Genes By Whole Exome Sequencing and Stromal-Cellular Interaction in Diffuse Large B-Cell Lymphoma
Authors: Vaishali Aggarwal, Radhika Srinivasan, Amanjit Bal, Pankaj Malhotra, Gaurav Prakash, Subhash Varma, Ashim Das
Journal: Blood (2015)
Long-Term Safety and Efficacy of Stem Cell Gene Therapy for ADA-SCID.
Authors: Alessandro Aiuti, Ulrike Benninghoff, Barbara Cassani, Federica Cattaneo, Luciano Callegaro, Grazia Andolfi, Massimiliano Mirolo, Samantha Scaramuzza, Sarah Marktel, Antonella Tabucchi, Filippo Carlucci, Martha Eibl, Memet Aker, Shimon Slavin, Fabio Ciceri, Roberto Miniero, Claudio Bordignon, Maria Grazia Roncarolo
Journal: Blood (2006)
Prognostic Significance Of a 4-Microrna Signature Targeting JAK2 In Classical Hodgkin Lymphoma
Authors: Alfons Navarro, Anna Gaya, Anna Cordeiro, Blanca Gonzalez-Farre, Marina Díaz-Beyá, Dolors Fuster, Carmen Martinez, Jordi Esteve, Antonio Martinez, Mariano Monzó
Journal: Blood (2013)
Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway.
Authors: Irene M. Ghobrial, Joanna M. Ghobrial, Patricia Bramati, Michael M. Timm, Ashock Kumar, Thomas E. Witzig, Neil Kay, Karen E. Hedin
Journal: Blood (2004)
Combination of Rituximab with Initial Chemotherapy Improves Outcome of Primary Mediastinal B-Cell Lymphoma: A Retrospective Analysis of a Single Institution Cohort
Authors: Abraham Avigdor, Tsvi Sirotkin, Noga Shemtov, Miriam Berkowicz, Yaron Davidovitz, Abraham Kneller, Izhar Hardan, Avichai Shimoni, Sara Apter, Isaac Ben-Bassat, Arnon Nagler
Journal: Blood (2007)
Favorable Outcome for Lymphoblastic Lymphoma (LL) After Frontline Therapy with the Hyper-CVAD Regimens: An Update.
Authors: Deborah A. Thomas, Stefan Faderl, Susan O'Brien, William G. Wierda, Farhad Ravandi, Guillermo Garcia-Manero, Srdan Verstovsek, Steven M. Kornblau, Luis Fayad, Jorge Cortes, Hagop M. Kantarjian
Journal: Blood (2009)
Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial.
Authors: M. Markova, Juliet N. Barker, John E. Wagner, Jeffrey S. Miller, Mukta Arora, Linda J. Burns, Margaret L. MacMillan, Tanya Repka, Bruce R. Blazar, Daniel J. Weisdorf
Journal: Blood (2004)
In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia
Authors: Rossana Maffei, Jenny Bulgarelli, Lara Rizzotto, Silvia Martinelli, Gian Matteo Rigolin, Stefania Fiorcari, Sara Martinelli, Giulia Debbia, Ilaria Castelli, Goretta Bonacorsi, Patrizia Zucchini, Rita Santachiara, Francesco Forconi, Davide Rossi, Luca Laurenti, Giuseppe A Palumbo, Daniele Vallisa, Antonio Cuneo, Gianluca Gaidano, Mario Luppi, Roberto Marasca
Journal: Blood (2012)
Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA-Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome
Authors: Alice Bertaina, Barbarella Lucarelli, Riccardo Masetti, Pietro Merli, Roberto Rondelli, Giuseppina Li Pira, Marco Andreani, Lavinia Grapulin, Daniela Pende, Michela Falco, Maria Rita Pinto, Valentina Bertaina, Maria Teresa Romano, Stefano Ceccarelli, Letizia Pomponia Brescia, Daria Pagliara, Alessandro Moretta, Lorenzo Moretta, Franco Locatelli
Journal: Blood (2015)
In Vivo CRISPR Screen Identifies TgWIP as a Toxoplasma Modulator of Dendritic Cell Migration
Authors: Lamba Omar Sangaré, Einar B. Ólafsson, Yifan Wang, Ninghan Yang, Lindsay Julien, Ana Camejo, Patricia Pesavento, Saima M. Sidik, Sebastian Lourido, Antonio Barragan, Jeroen P.J. Saeij
Journal: Cell Host & Microbe (2019)
Elevated Homologous Recombination Induces Karyotypic Changes and Predicts Poor Clinical Outcome In Multiple Myeloma
Authors: Jagannath Pal, Jeffrey Sawyer, Samir B. Amin, Cheng Li, Puru Nanjappa, Saem Lee, Stephane Minvielle, Hervé Avet-Loiseau, Masood Shammas, Nikhil C. Munshi
Journal: Blood (2010)
Spectrum of Concomitant and Subsequently Diagnosed Second Malignancies in Patients with Chronic Myelomonocytic Leukemia
Authors: Daniela Barraco, Terra L. Lasho, Christy Finke, Aref Al-Kali, Michelle Elliott, Mark R. Litzow, Naseema Gangat, Curtis A. Hanson, Ayalew Tefferi, Mrinal M Patnaik
Journal: Blood (2016)
B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor
Authors: James N Kochenderfer, Mark E. Dudley, Steven Feldman, Wyndham H. Wilson, David Spaner, Laura Devillier, Robert Carpenter, Debbie-Ann N. Nathan, Irina Maric, Richard A. Morgan, Steven A. Rosenberg
Journal: Blood (2011)
Implications of the Association of Social Exclusion With Mental Health
Authors: Andreas Heinz, Xudong Zhao, Shuyan Liu
Journal: JAMA Psychiatry (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion
Authors: Chandima Divithotawela, Marcelo Cypel, Tereza Martinu, Lianne G. Singer, Matthew Binnie, Chung-Wai Chow, Cecilia Chaparro, Thomas K. Waddell, Marc de Perrot, Andrew Pierre, Kazuhiro Yasufuku, Jonathan C. Yeung, Laura Donahoe, Shaf Keshavjee, Jussi M. Tikkanen
Journal: JAMA Surgery (2019)

The mortality rate for individuals on the wait list for lung transplant is 15% to 25%, and still only 20% of lungs from multiorgan donors are used for lung transplant. The lung donor pool may be increased by assessing and reconditioning high-risk extended criteria donor lungs with ex vivo lung perfusion (EVLP), with similar short-term outcomes.To assess the long-term outcomes of transplant recipients of donor lungs treated with EVLP.This retrospective cohort single-center study was conducted from August 1, 2008, to February 28, 2017, among 706 recipients of donor lungs not undergoing EVLP and 230 recipients of donor lungs undergoing EVLP.Donor lungs undergoing EVLP.The incidence of chronic lung allograft dysfunction and allograft survival during the 10-year EVLP era were the primary outcome measures. Secondary outcomes included donor characteristics, maximum predicted percentage of forced expiratory volume in 1 second, acute cellular rejection, and de novo donor-specific antibody development.This study included 706 patients (311 women and 395 men; median age, 50 years [interquartile range, 34-61 years]) in the non-EVLP group and 230 patients (85 women and 145 men; median age, 46 years [interquartile range, 32-55 years]) in the EVLP group. The EVLP group donors had a significantly lower mean (SD) Pao2:fraction of inspired oxygen ratio than the non-EVLP group donors (348 [108] vs 422 [88] mm Hg; P < .001), higher prevalence of abnormal chest radiography results (135 of 230 [58.7%] vs 349 of 706 [49.4%]; P = .02), and higher proportion of smoking history (125 of 204 [61.3%] vs 322 of 650 [49.5%]; P = .007). More recipients in the EVLP group received single-lung transplants (62 of 230 [27.0%] vs 100 of 706 [14.2%]; P < .001). There was no significant difference in time to chronic lung allograft dysfunction between the EVLP and non-EVLP group (70% vs 72% at 3 years; 56% vs 56% at 5 years; and 53% vs 36% at 9 years; log-rank P = .68) or allograft survival between the EVLP and non-EVLP groups (73% vs 72% at 3 years; 62% vs 58% at 5 years; and 50% vs 44% at 9 years; log-rank P = .97) between the 2 groups. All secondary outcomes were similar between the 2 groups.Since 2008, 230 of 936 lung transplants (24.6%) in the Toronto Lung Transplant Program were performed after EVLP assessment and treatment. Use of EVLP-treated lungs led to an increase in the number of patients undergoing transplantation, with comparable long-term outcomes.
Serum Amyloid Protein A 1 (hSAA1) Is Overexpressed in Myelodysplastic Syndromes and Potentially Mediates Toll-Like Receptor 2 Innate Immunity Signaling in CD34+ Hematopoietic Stem Cells
Authors: Yue Wei, Carlos E. Bueso-Ramos, Hui Yang, Yu Jia, Hong Zheng, Simona Colla, Martin Nguyen, Michael Fernandez, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2012)
CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways
Authors: Patrick Hagner, Maria Wang, Suzana Couto, Mike Breider, Celia Fontanillo, Matthew Trotter, Chad C Bjorklund, Courtney G. Havens, Heather K Raymon, Rama Krishna Narla, Leo Barnes, Michelle Waldman, Tom Daniel, Anke Klippel, Michael Pourdehnad, Anjan Thakurta, Rajesh Chopra, Anita K. Gandhi
Journal: Blood (2014)
Mechanisms of Improvement of Erythropoiesis with Low Dose Deferasirox in Low Risk Myelodysplastic Syndromes
Authors: Mathieu Meunier, Sarah Ancelet, Christine Lefebvre, Josiane Arnaud, Catherine Garrel, Yan Wang, Patrice Faure, Benoit Polack, Jean-Yves Cahn, Sophie Park
Journal: Blood (2016)
In suspected MI without ST elevation, a risk tool including hs-cTnI or hs-cTnT predicted diagnosis and 30-d outcomes
Authors: Eric R. Bates
Journal: Annals of Internal Medicine (2019)

Source Citation Neumann JT, Twerenbold R, Ojeda F, et al. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med. 2019;380:2529-40. 31242362
RNA Splicing Modulation Impairs Acute Myeloid Leukemia Stem Cell Maintenance
Authors: Leslie A Crews, Larissa Balaian, Heather Leu, Nathaniel Delos Santos, Angela C Court, Anil Sadarangani, Maria A. Zipeto, James J La Clair, Reymundo Villa, Sheldon Morris, Rainer F. Storb, Anna Kulidjian, Edward D. Ball, Michael D Burkart, Catriona Jamieson
Journal: Blood (2015)
Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status
Authors: Caroline R Cantilena, Xin Zhao, Sachiko Kajigaya, Neil Dunavin, Xin Tian, Stephen A. Strickland, Bipin N. Savani, Sanjay R. Mohan, Katayoun Rezvani, Xingmin Feng, Danielle M. Townsley, Minoo Battiwalla, Sawa Ito, Austin John Barrett
Journal: Blood (2015)
Non-Adherence to Oral 6-Mercaptopurine (6MP) Explains Ethnic Differences In Disease-Free Survival In Children with Acute Lymphoblastic Leukemia (ALL) – a Children's Oncology Group (COG) Study (AALL03N1)
Authors: Smita Bhatia, Wendy Landier, Muyun Shangguan, Lindsey Hageman, Wendy Leisenring, Nancy Kornegay, Mary V. Relling, F. Lennie Wong
Journal: Blood (2010)
Peripheral Blood Stem Cell (PBSC) Mobilization in Patients with Multiple Myeloma: Low Dose Versus Intermediate Dose Cyclophosphamide.
Authors: Devendra K. Hiwase, Anthony P. Schwarer, Joe J. Mckendrick, Geraldine M. Bollard, Smita D. Hiwase, Bailey M. Michael
Journal: Blood (2005)
Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke
Authors: S. Claiborne Johnston, Jordan J. Elm, J. Donald Easton, Mary Farrant, William G. Barsan, Anthony S. Kim, Anne S. Lindblad, Yuko Y. Palesch, Karla G. Zurita, Gregory W. Albers, Brett L. Cucchiara, Dawn O. Kleindorfer, Helmi L. Lutsep, Claire Pearson, Pramod Sethi, Nirali Vora
Journal: Circulation (2019)

In patients with acute minor ischemic stroke or high-risk transient ischemic attack enrolled in the POINT trial (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke [POINT] Trial), the combination of clopidogrel and aspirin for 90 days reduced major ischemic events but increased major hemorrhage in comparison to aspirin alone.In a secondary analysis of POINT (N=4881), we assessed the time course for benefit and risk from the combination of clopidogrel and aspirin. The primary efficacy outcome was a composite of ischemic stroke, myocardial infarction, or ischemic vascular death. The primary safety outcome was major hemorrhage. Risks and benefits were estimated for delayed times of treatment initiation using left-truncated models.Through 90 days, the rate of major ischemic events was initially high then decreased markedly, whereas the rate of major hemorrhage remained low but relatively constant throughout. With the use of a model-based approach, the optimal change point for major ischemic events was 21 days (0-21 days hazard ratio 0.65 for clopidogrel-aspirin versus aspirin; 95% CI, 0.50-0.85; P=0.0015, in comparison to 22-90 days hazard ratio, 1.38; 95% CI, 0.81-2.35; P=0.24). Models showed benefits of clopidogrel-aspirin for treatment delayed as long as 3 days after symptom onset.The benefit of clopidogrel-aspirin occurs predominantly within the first 21 days, and outweighs the low, but ongoing risk of major hemorrhage. When considered with the results of the CHANCE trial (Clopidogrel in High-Risk Patients With Non-disabling Cerebrovascular Events), a similar trial treating with clopidogrel-aspirin for 21 days and showing no increase in major hemorrhage, these results suggest that limiting clopidogrel-aspirin use to 21 days may maximize benefit and reduce risk after high-risk transient ischemic attack or minor ischemic stroke.URL: https://www.clinicaltrials.gov. Unique identifier: NCT00991029.
Induction Of Apoptosis By The Dual PI3K/Mtor Inhibitor NVP-BEZ235 Is Impaired By a Profound G1/G0 Arrest In Acute Leukemia Which Can Be Overcome By Combination Approaches
Authors: Kerstin M Kampa-Schittenhelm, Figen Akmut, Barbara Illing, Marcus M Schittenhelm
Journal: Blood (2013)
Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.
Authors: Simone Boehrer, Lorenzo Galluzzi, Lionel Ades, Celine Fouassier, Claude Gardin, Pierre Fenaux, Guido Kroemer
Journal: Blood (2009)
In Acute Leukemia, the Polymorphism −211C&gt;T in the Promoter Region of the Multidrug Resistance-Associated Protein 3 (MRP3) Is Not Associated with the Expression Level of the Gene.
Authors: Claus Dorfel, Axel Sauerbrey, Bernd Gruhn, Felix Zintl, Daniel Steinbach
Journal: Blood (2005)
Activation of STAT5 contributes to tumor growth and epithelial-mesenchymal transition in head and neck cancer
Authors: Vivian Wy Lui, Sichuan Xi, Chai L. Raymond, Priya Koppikar, Jennifer R. Grandis
Journal: Cancer Research (2006)

4830  Signal Transducer and Activator of Transcription 5 (STAT5) is activated in squamous cell carcinoma of the head and neck (SCCHN). However, the role of STAT5 activation in SCCHN carcinogenesis is incompletely understood. In this study, the effects of constitutive STAT5 activation in SCCHN were investigated using stable clones expressing constitutively active mutants of STAT5a or STAT5b isoforms in SCCHN cell lines. The growth rate of the stable clones expressing the activating mutations (STAT5a 1*6 and STAT5b 1*6) was about 49 % and 68% higher than that of the vector control (pUSEamp), respectively. Constitutive activation of STAT5 also significantly increased the transforming efficiency of the SCCHN cells in vitro (by soft agar-transformation assay). The activated STAT5 clones showed increased tumor growth in vivo in a xenograft model of SCCHN. At day 25 after tumor inoculation, the tumor volumes of the activating STAT5 mutant clones were twice of that of the vector-transfected controls. STAT5 activation also resulted in increased invasion of SCCHN cells through Matrigel. Finally, the STAT5a 1*6 and STAT5b 1*6 clones demonstrated changes consistent with an epithelial-mesenchymal transition (EMT) including decreased expression of E-cadherin and increased vimentin, in comparison to the pUSEamp control. These results suggest that constitutive STAT5 signaling enhances tumor growth, invasion and EMT in SCCHN.
Porcine and Ovine Mucosal Heparins and Their Depolymerized Derivatives Are Comparable in Contrast to Their Bovine Equivalents
Authors: Olivia Bouchard, Debra Hoppensteadt, Paula Maia, Alice Silva de Castro, Emmanuele Kumar, Nil Guler, Walter Jeske, Daniel Kahn, Jeanine M. Walenga, Erwin Coyne, Yimng Yao, Jawed Fareed
Journal: Blood (2016)
Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn 7)? Results of a Retrospective Study From the GFM and GESMD Registries
Authors: María Díez-Campelo, Raphael Itzykson, Silvia M Rojas, Céline Berthon, Elisa Luño, Odile Beyne-Rauzy, Jaime Perez-Oteyza, Norbert Vey, Joan Bargay, Sophie Park, Teresa Cedena, Dominique Bordessoule, Juan A Muñoz, Emmanuel Gyan, Esperanza Such, Sorin Visanica, Luis Benlloch, Stéphane de Botton, Jesús M Hernández-Rivas, Shanti Ame, Aspasia Stamatoullas, Jacques Delaunay, Celia Salanoubat, Françoise Isnard, Guillermo Sanz, Romain Guieze, Consuelo Cañizo, Pierre Fenaux
Journal: Blood (2012)
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis
Authors: Fausto Castagnetti, Gabriele Gugliotta, Massimo Breccia, Giorgina Specchia, Elisabetta Abruzzese, Luciano Levato, Francesco Cavazzini, Alessandra Iurlo, Fabio Stagno, Dario Ferrero, Ferdinando Porretto, Bruno Martino, Serena Rupoli, Tamara Intermesoli, Carmen Fava, Francesca Palandri, Claudia Venturi, Simona Soverini, Nicoletta Testoni, Giuliana Alimena, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2012)
Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.
Authors: Brian A. Di Carlo, Jessica L. Stern, Michael Schuster, Tsiporah Shore, John Harpel, Roger Pearse, Faiza Zafar, Joanne Dymek, Jessy Ryan, David Jayabalan, Selina Chen-Kiang, Scott Ely, John P. Leonard, Morton Coleman, Ruben Niesvizky
Journal: Blood (2006)
Integrative Analysis of Lincrna Expression and Clinical Annotations Reveals a Signature of 17 Genes with Prognostic Significance in Acute Myeloid Leukemia (AML)
Authors: Dominik Beck, Cintia Palu, Anushi Shah, Tobias Herold, Jake Olivier, Peter J.M. Valk, Ruud Delwel, Stefan K Bohlander, Jason W Wong, John E Pimanda
Journal: Blood (2014)
Role of LIM Kinase in Oncogenic Signaling from FLT3 and KIT Receptors and Its Targeting in Myeloid Leukemia
Authors: Ruchi Pandey, Raghuveer Mali, Anindya Chatterjee, Fabrice Paublant, Renaud Prudent, Laurence Lafanechere, Reuben Kapur
Journal: Blood (2015)
BCL-2 Inhibition By ABT-199 (Venetoclax/GDC-0199) and p53 Activation By RG7388 (Idasanutlin) Reciprocally Overcome Leukemia Apoptosis Resistance to Either Strategy Alone: Efficacy and Mechanisms
Authors: Rongqing Pan, Vivian Ruvolo, Hong Mu, Zhuanzhen Zheng, Joel Leverson, Kensuke Kojima, Marina Konopleva, Gwen Nichols, Michael Andreeff
Journal: Blood (2015)
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren’s Disease and May Not Benefit from Local Therapy
Authors: Amie E Jackson, Michael Mian, Christina H. Kalpadakis, Gerassimos A Pangalis, Anastasios Stathis, Elena Porro, Ellen D McPhail, Thomas M Habermann, Kay M. Ristow, Franco Cavalli, Grzegorz S. Nowakowski, Emanuele Zucca
Journal: Blood (2014)